Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SRF617 |
Synonyms | |
Therapy Description |
SRF617 is a monoclonal antibody that binds to CD39 and inhibits the conversion of ATP to AMP, potentially resulting in enhanced adaptive and innate immune response against tumor cells (NCI Thesaurus). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SRF617 | SRF-617|SRF 617 | CD39 Antibody 5 | SRF617 is a monoclonal antibody that binds to CD39 and inhibits the conversion of ATP to AMP, potentially resulting in enhanced adaptive and innate immune response against tumor cells (NCI Thesaurus). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04336098 | Phase I | SRF617 | Study of SRF617 in Patients With Advanced Solid Tumors | Completed | USA | CAN | 0 |